Agilon Health Inc.

Company Overview

Business Model: agilon health, inc. transforms healthcare by empowering primary care physicians (PCPs) to manage the total healthcare needs of attributed Medicare patients through a Medicare-centric, globally capitated line of business. The model involves forming wholly-owned risk-bearing entities (RBEs) in local geographies that contract with payors for monthly payments (global capitation) to manage patient care. These RBEs then enter into long-term professional service agreements, typically 20 years, with anchor physician groups, providing base compensation and sharing in savings from improved quality of care and reduced costs. The business model is built on the agilon platform (technology, people, process, capital), a long-term physician partnership approach, and a collaborative network of community-based physicians.

Market Position: The healthcare industry is highly competitive and fragmented. agilon health, inc. competes against other value-based care providers, local provider networks, hospitals, and health systems. While some competitors utilize elements of its multi-payor, globally capitated risk model, the Company believes its platform, partnership, and network model is first-of-its-kind and enables favorable competition. As of December 31, 2025, the Company partnered with 28 anchor physician groups across 30 geographies in 12 U.S. states, serving approximately 511,000 Medicare Advantage (MA) members and 114,000 Medicare fee-for-service (FFS) beneficiaries through nine Accountable Care Organizations (ACOs) participating in the Centers for Medicare & Medicaid Services’ (CMS) ACO Realizing Equity, Access, and Community Health (ACO REACH) Model and Medicare Shared Savings Program (MSSP).

Recent Strategic Developments:

• NYSE Listing Compliance: On November 5, 2025, agilon health, inc. received notice from the NYSE for non-compliance with the $1.00 average closing price requirement. The Company is pursuing a reverse stock split, subject to stockholder approval at a special meeting on March 17, 2026, to regain compliance.
• Leadership Transition: Steven Sell resigned as Chief Executive Officer, President, and board member on July 29, 2025. The Company is currently managed by interim principal executive officers.
• CMS ACO Model Evolution: CMS announced the ACO REACH Model will terminate at the end of 2026, to be replaced by the Long-term Enhanced ACO Design (LEAD) Model starting January 1, 2027. The Company is evaluating participation in LEAD, noting uncertainties in its technical, operational, and financial aspects. For 2026, three ACOs transitioned from ACO REACH to MSSP, and two partner groups moved between ACOs within ACO REACH due to technical adjustments.
• Partnership Exits: Membership declines in 2025 were primarily attributed to partnership exits during 2024.

Geographic Footprint: As of December 31, 2025, agilon health, inc. operates in 30 geographies across 12 states: Connecticut, Georgia, Illinois, Kentucky, Michigan, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Tennessee, and Texas.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: -2.7%
• Operating Margin: -7.8%
• Net Margin: -6.6%

Investment in Growth:

• R&D Expenditure: Not explicitly disclosed as a separate line item.
• Capital Expenditures: $43.1 million (includes purchase of property and equipment, and intangible assets)
• Strategic Investments: $2.0 million (investments in loans receivable and other)

Business Segment Analysis

agilon health, inc. operates as a single operating and reportable segment, focusing on a Medicare-centric, capitated line of business. The Company's Chief Operating Decision Maker (CODM) evaluates performance and allocates resources on a consolidated basis.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No repurchases in 2025 or 2024. In 2023, the Company repurchased $200.0 million (9.6 million shares).
• Dividend Payments: agilon health, inc. has never declared or paid cash dividends and does not intend to for the foreseeable future, prioritizing debt repayment, growth funding, working capital, and general corporate purposes.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $173.7 million
• Total Debt: $35.0 million (Secured Term Loan)
• Net Cash Position: $138.7 million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The Secured Term Loan, originally maturing February 18, 2026, was extended to February 18, 2028, via an amendment on February 10, 2026. As of December 31, 2025, $19.2 million is current, and $15.8 million is long-term.

Cash Flow Generation:

• Operating Cash Flow: $(105.8) million (net cash used in operating activities)
• Free Cash Flow: Not explicitly disclosed.
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: agilon health, inc.'s model empowers PCPs to manage total healthcare needs for attributed Medicare patients. The agilon platform supports this by providing technology, people, process, and capital to facilitate the transition to a Total Care Model. This includes identifying care gaps, integrating with payors, sustaining practices, and identifying opportunities for improved outcomes. The Company forms RBEs that contract with payors and physician groups, with RBEs bearing financial responsibility for medical costs.

Supply Chain Architecture: Not explicitly detailed in the filing.

Key Suppliers & Partners:

• Physician Partners: 28 anchor physician groups across 30 geographies. These groups are critical for delivering care and managing costs.
• Health Plan Payors: Contracts with large national health plans (e.g., Humana, Aetna, UnitedHealthcare) and smaller local/regional insurers.
• Other Providers: Relationships with hospitals, specialists, and ancillary providers who typically contract directly with payors.
• Technology Partners: Not explicitly named, but the Company relies on third-party software and data.

Facility Network: agilon health, inc. leases approximately 72,000 gross square feet across 13 office facilities.

• Manufacturing: Not applicable.
• Research & Development: Not explicitly detailed, but the Company has proprietary technology (CORE, HCC Manager, Minerva) that is continuously refined.
• Distribution: Not explicitly detailed.

Operational Metrics:

• MA members: 511,000 (down 3% from 2024)
• CMS ACO Models attributed beneficiaries: 114,000 (down 13% from 2024)
• Platform support costs: $160.0 million (3% of revenue)

Market Access & Customer Relationships

Go-to-Market Strategy: agilon health, inc. focuses on outreach to existing community-based physician groups to join its platform and expand its geographic reach. A dedicated business development team identifies potential physician partners. The Company also supports local branding and educational strategies for Medicare-eligible patients to evaluate their Medicare options. Distribution Channels:

• Direct Sales: Implied through direct engagement with physician groups.
• Channel Partners: Health plan payors are responsible for marketing their products and services directly to consumers, with whom agilon health, inc. contracts.
• Digital Platforms: Not explicitly detailed, but the Company's marketing and communications team develops educational communication programs and materials.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Key payors include Payor A (17% of total revenue), Payor B (16%), Payor C (13%), and Payor E (10%) in 2025.
• Strategic Partnerships: Long-term partnerships with community-based physician groups, typically 20 years in duration.
• Customer Concentration: Substantially all revenue is from federal government healthcare programs, with significant concentration among a limited number of key payors.

Geographic Revenue Distribution:

• [Region/Country]: Not explicitly broken down by region/country in the filing, but operations span 12 U.S. states.
• Growth Markets: The Company aims to expand into new geographies and grow existing markets.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The healthcare industry is highly competitive and fragmented, with ongoing consolidation among physician groups and payors. The market is evolving towards value-based care models, incentivizing physicians for improving cost and quality of healthcare. Government policies, particularly for Medicare Advantage, significantly influence market dynamics. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: agilon health, inc. faces competition from other entities providing value-based care services, local provider networks, hospitals, and health systems. Large, well-financed payors may also develop their own managed care services or expand relationships with competing networks. Emerging Competitive Threats: New entrants, disruptive technologies (including advanced AI and quantum computing), and alternative solutions are potential threats. Competitive Response Strategy: The Company's strategy relies on its differentiated platform, partnership, and network model to attract and retain physician partners and payors, and to replicate its model's success in new geographies.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Government Program Dependence: Substantially all revenue is from federal government healthcare programs (MA program). Reductions in reimbursement rates, changes to risk-adjustment methodologies (e.g., RAPS to EDS transition, RADV audits), or discontinuation of programs (e.g., ACO REACH to LEAD Model transition) could adversely affect revenue and profitability.
• Competition: Highly competitive and fragmented industry, with consolidation among physician groups and payors potentially increasing bargaining power of competitors or reducing market opportunity.
• Economic Conditions: Uncertain or adverse macroeconomic conditions (inflation, labor shortages, high interest rates) could impact MA enrollment, benefit structures, and the ability to raise capital.
• Membership Reduction: Significant reduction in MA membership due to various factors (e.g., failure to retain partners/members, payor non-renewal, low quality of care, negative publicity, changes in STAR ratings) could adversely affect financial performance.
• Physician Partner Challenges: Transitioning to a Total Care Model can be challenging for physician partners, potentially leading to an inability to attract/retain successful partners or recoup startup costs.
• Payor Contract Terms: Inability to secure MA payor contracts in new geographies or at favorable financial terms could impact growth and financial targets.

Operational & Execution Risks

Supply Chain Vulnerabilities: Not explicitly detailed, but reliance on third-party software, data, infrastructure, and bandwidth providers introduces operational risks.

• Supplier Dependency: Reliance on third-party software and data providers; loss of access or increased restrictions could significantly increase expenses or delay services.
• Geographic Concentration: Not explicitly detailed, but expansion into new geographies presents risks due to differing stakeholder preferences, MA enrollment rates, reimbursement rates, and regulatory environments.
• Capacity Constraints: Physician partners may face difficulties recruiting additional PCPs to meet increased patient demand, impacting growth.
• Information Systems: Security breaches, cybersecurity attacks, data loss, or other disruptions to information systems (including those of third-party providers) could compromise sensitive information, expose the Company to liability, and adversely affect operations.
• Data Accuracy: Inaccuracy in estimates of risk adjustment factors, medical services expense, and incurred but not reported (IBNR) claims could lead to financial losses. Dependence on physician partners for accurate and timely diagnosis data is critical, as inaccuracies could result in nonpayment, recoupments, or FCA liability.
• Intangible Asset Value: Failure to realize the full value of intangible assets (e.g., goodwill, trade names) could lead to impairment charges.

Financial & Regulatory Risks

Market & Financial Risks:

• Net Losses: History of net losses and expectation of increasing expenses in the future, with no guarantee of achieving or maintaining profitability.
• Capital Availability: May require substantial additional capital, which might not be available on acceptable terms or at all, potentially restricting operational flexibility or diluting stockholders.
• Indebtedness: Existing indebtedness and potential for incurring more debt, with covenants that restrict operational flexibility and could lead to default if breached.
• Foreign Exchange: Not explicitly detailed as a material risk.
• Credit & Liquidity: Dependence on subsidiaries for cash, with restrictions on distributions from subsidiaries due to regulatory or contractual obligations (e.g., Credit Facility covenants, risk-bearing capital requirements). Regulatory & Compliance Risks:
• Healthcare Regulation: Heavily regulated industry at federal, state, and local levels. Non-compliance with laws (e.g., CPOM, fee-splitting, FCA, AKS, Stark Law, HIPAA, TCPA, antitrust) could result in civil/criminal damages, fines, sanctions, or exclusion from government programs.
• Insurance Licensing: Uncertainty regarding state regulations on downstream risk-sharing arrangements; failure to obtain or maintain required insurance licenses or certificates of authority could lead to penalties.
• Tax Laws: Changes in tax laws and regulations (e.g., "One Big Beautiful Bill Act," OECD Pillar Two) or related judgments could materially impact financial condition.
• Legal Proceedings: Exposure to various litigation matters, including securities class action lawsuits and stockholder derivative lawsuits, which could result in substantial costs and diversion of management attention.

Geopolitical & External Risks

Geopolitical Exposure: Geopolitical events (e.g., war in Ukraine, Middle East tensions) could lead to retaliatory cyberattacks or other actions disrupting operations. Trade Relations: Not explicitly detailed as a material risk. Sanctions & Export Controls: Not explicitly detailed as a material risk.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• CORE technology platform: A proprietary system supporting rapid transition to a Total Care Model.
• HCC Manager risk adjustment software application: Proprietary software aiding in the aggregation and analysis of third-party data.
• Minerva clinical data platform: Proprietary system for clinical data management and insights. Innovation Pipeline: Technology is continuously refined to support the needs of the platform and partners. The Company continually assesses methods for protecting intellectual property.

Intellectual Property Portfolio:

• Patent Strategy: Does not currently hold patents for CORE, HCC Manager, or Minerva, but continually assesses and may pursue protections in the future.
• Trademark Strategy: Registered "agilon health" (expires 2028) and "Medicare Quick Thinking" (expires 2034) trademarks in the U.S., with other applications filed.
• Licensing Programs: Not explicitly detailed.
• IP Litigation: Not explicitly detailed.

Technology Partnerships:

• Strategic Alliances: Not explicitly detailed, but relies on third-party software and data providers.
• Research Collaborations: Not explicitly detailed.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Steven Sell resigned as CEO on July 29, 2025. The Company is currently managed by an Office of the Chairman, including interim principal executive officers. The Company's success depends on its ability to hire and retain qualified personnel, and competition for such talent is intense.

Board Composition: The Board of Directors oversees the Company's human capital practices and cybersecurity risk management, supported by the Audit Committee and Compliance and Quality Committee. Board members include Ronald A. Williams (Chairman), Ravi Sachdev (Vice Chairman), Sharad Mansukani, M.D., William Wulf, M.D., Karen McLoughlin, Diana L. McKenzie, and Silvana Battaglia.

Human Capital Strategy

Workforce Composition:

• Total Employees: 856 employees as of December 31, 2025, substantially all full-time.
• Geographic Distribution: Not explicitly detailed, but employees support geographies across the U.S.
• Skill Mix: Not explicitly detailed, but the Company seeks qualified personnel with skills and experience in the Total Care Model.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Supported by a dedicated People team, comprehensive employee orientation, and manager toolkits.
• Retention Metrics: Not explicitly detailed, but the Company acknowledges employee turnover and the need to enhance pay and benefits to compete for talent.
• Employee Value Proposition: Comprehensive and competitive compensation and benefits (base pay, short/long-term incentives, 401(k), health/welfare, paid time off, flexible work, family leave). Practices to promote fair and consistent pay decisions (benchmarking, pay transparency, consistent annual merit/bonus processes).

Diversity & Development:

• Diversity Metrics: Not explicitly detailed, but the Company is committed to an inclusive and diverse workplace, offering training on inclusive leadership, anti-harassment, and anti-discrimination.
• Development Programs: Offers a range of learning opportunities, including courses for technical/role-specific skills, leadership development, and career progression. Supports continuing professional education and encourages coaching/mentoring.
• Culture & Engagement: Promotes a positive culture through local/national events, recognition awards, and annual employee engagement surveys.

Environmental & Social Impact

Environmental Commitments: Not explicitly detailed in the filing. Climate Strategy: Not explicitly detailed in the filing. Supply Chain Sustainability: Not explicitly detailed in the filing. Social Impact Initiatives: Not explicitly detailed in the filing.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed in the filing.
• Economic Sensitivity: Unfavorable economic conditions could impact MA plan enrollment, change benefit structures, or weaken the ability to raise capital.
• Industry Cycles: The healthcare industry is subject to structural change and rapid evolution, with regulatory and economic conditions leading to consolidation.

Planning & Forecasting: The Company's cash flows are impacted by the timing of receipts from payors and the level of operating and general and administrative expenses. Medical services revenue and expense estimates are based on clinical disease conditions, risk adjustment factors, utilization trends, and historical payment patterns.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Corporate Practice of Medicine (CPOM): Laws in some states prohibit non-physician entities from practicing medicine or controlling medical decisions. The Company structures its RBEs and physician partnerships to comply, but violations could lead to fines, penalties, or restructuring.
• Fee-Splitting Prohibitions: Laws in some states prohibit sharing professional fees with non-providers. The Company structures arrangements to comply, but violations could lead to disciplinary action or monetary damages.
• False Claims Acts (FCA): Subject to federal and state laws prohibiting false information submission for medical claims. Inaccuracies in diagnosis data or coding could lead to civil liability (treble damages, penalties) and criminal penalties.
• Anti-Kickback Statute (AKS): Prohibits offering/receiving remuneration to induce referrals for federal healthcare programs. The Company structures arrangements to comply or fit safe harbors.
• Stark Law: Prohibits physician self-referrals for Designated Health Services (DHS) if a financial relationship exists, unless an exception applies. The Company structures arrangements to comply, noting exceptions for risk-sharing and physician incentive plans.
• Section 1876 of the Social Security Act: Prohibits MA plans and downstream entities from compensation arrangements that reduce/limit services to members.
• Health Care Fraud Statute: Criminal statute prohibiting schemes to defraud healthcare benefit programs.
• Civil Monetary Penalties Law (CMPL): Authorizes penalties for prohibited conduct, including false claims or offering inducements to beneficiaries.
• Federal and State Insurance and Managed Care Laws: Regulation of downstream risk-sharing arrangements varies by state; may require insurance licenses or certificates of authority.
• Healthcare Reform: The ACA and its underlying programs are subject to uncertainty, with potential for further legal challenges, repeal, or amendment. CMS Innovation Center models (ACO REACH, LEAD) are evolving and could impact reimbursement.
• Privacy and Security Requirements (HIPAA, HITECH, 21st Century Cures Act): Subject to federal and state laws governing PHI and personally identifiable information. Non-compliance could lead to significant liability, penalties, and reputational harm.
• Consumer Protection Laws (TCPA): Regulates phone/text advertising; violations could lead to significant damage awards.
• Competition and Antitrust Laws (Sherman Act, FTC Act, Clayton Act): Subject to laws governing competition; growth and long-term contracts could expose the Company to investigations or litigation.
• U.S. Foreign Corrupt Practices Act (FCPA) and Anticorruption Laws: Prohibits bribery of foreign officials; also subject to Brazil's Clean Companies Act and India's Prevention of Corruption Act.
• Other Laws: State licensing/registration for utilization review or claims processing; physician partners subject to professional credentialing and ethics. International Compliance: Subject to foreign anticorruption laws in locations like Brazil and India.

Trade & Export Controls: Not explicitly detailed as a material risk. Legal Proceedings:

• Securities Class Action Lawsuits: Currently subject to two punitive class action lawsuits (Consolidated Securities Matter, Vandersluis v. agilon health, Inc.) alleging securities fraud related to financial guidance, medical margin, and Adjusted EBITDA results.
• Stockholder Derivative Lawsuits: Currently subject to two consolidated stockholder derivative lawsuits (Consolidated Derivative Matters) and one new lawsuit (Sinha v. Sell et al.) alleging breach of fiduciary duty and other claims.
• Regulatory Investigations: From time to time involved in inquiries, reviews, audits, and investigations by governmental agencies and private payors.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Not explicitly stated, but the Company has a history of net losses and a full valuation allowance on its U.S. federal and state net deferred tax assets.
• Geographic Tax Planning: Subject to federal and state taxes in the U.S. and other countries. Has unremitted earnings from non-U.S. subsidiaries intended for indefinite reinvestment.
• Tax Reform Impact: The "One Big Beautiful Bill Act" (signed July 4, 2025) did not have a material impact on the 2025 tax provision. The OECD Pillar Two model rules (15% global minimum tax) are not expected to have a material impact on the 2025 tax provision.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains managed care errors and omissions insurance, along with director and officers insurance. Physician partners are required to carry medical malpractice insurance.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.